Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD0T1U)

Drug Name

Depudecin Drug Info

Synonyms

(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[3]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[4]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[3]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[7]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[8]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[9]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	HDAC inhibitors repress the polycomb protein BMI1. Cell Cycle. 2010 Jul 15; 9(14): 2722-2730.
2	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
3	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
4	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
7	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
8	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
9	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
10	2011 Pipeline of 4SC AG.